FOLH1 and neutropenia: Heck et al. presented the largest cohort of patients (n = 100) treated with [177Lu]Lu-PSMA I&T and showed that treatment-related toxicities were mainly hematologic, including grade III/IV toxicities, such as anemia (9%), thrombocytopenia (4%), and neutropenia (6%).